Shortcut method in drug development

The majority of promising new drug candidates are effective only within the body's cells, but quick general methods of determining intracellular drug quantities are lacking. A team of researchers, headed by the Drug Delivery Group at Uppsala University, may now be on the track of a solution through a new, small-scale and fast method of determining a drug's bioavailability (the fraction available to work in biological processes) inside cultured cells. By measuring the unbound quantity of the drug in the cells, the method takes into account how the drug partly "disappears" when it binds to various cell components where it cannot exert its intended effect. This "disappearing" proportion of the drug varies from one molecule to another and has hitherto been hard to predict, but can now be easily determined with the researchers' small-scale method.

In the latest issue of the journal Proceedings of the National Academy of Sciences (PNAS), a research group at Uppsala University presents a new, small-scale method that may become a smart shortcut for determining the "bioavailability" of a pharmaceutical drug within cells.

"Finding out how a therapeutic drug affects the body means having to consider many different factors that can influence the cells' internal environment. Our method may be a way of substantially facilitating this stage."

The speaker, Uppsala University's Professor Per Artursson, bears primary responsibility for the joint study under way with colleagues at the Chemical Biology platform in SciLifeLab (created jointly by Uppsala and Stockholm Universities, Karolinska Institute and KTH Royal Institute of Technology) and GlaxoSmithKline in Stevenage, UK.

The research group has also demonstrated that, measured with the new method, bioavailability can be used to predict the effects of the drug molecules in various more advanced cell models for specific therapeutic areas, such as cancer, inflammation and dementia disorders.

"It takes time to develop models for specific therapeutic areas, so our method may be especially useful in early stages of drug development. Major pharmaceutical drug companies have already shown great interest and the method is now being offered on the SciLifeLab Drug Discovery and Development platform," Artursson says.

The scientists are currently investigating whether the method can predict effects of drugs in the body as well. This is more complicated than a cell culture. Since taking blood samples is simple while sampling tissue is considerably more difficult, bioavailability is often predicted on the basis of drug concentrations in the blood - a fairly blunt instrument.

The proportion of a drug entering the target cell may be either higher or lower than in the blood. The drug may, for example, bind to the cell's fat molecules, break down or be transported out of the cell. These mechanisms reduce the available fraction of the drug inside the cell, i.e. its intracellular bioavailability. Retrospective correction factors must therefore often be introduced to allow for these mechanisms in the use of "pharmacokinetic models" to study a drug's route of administration into the body.

"Our preliminary studies show that replacing the correction factors with a simple determination of local bioavailability in the cells seems to be possible. But more experiments are required before we know how applicable our principle is at tissue and organism level. Clearly, intracellular bioavailability is on the way to becoming an important early instrument in pharmaceutical drug research," Artursson says.

André Mateus, Laurie J. Gordon, Gareth J. Wayne, Helena Almqvist, Hanna Axelsson, Brinton Seashore-Ludlow, Andrea Treyer, Pär Matsson, Thomas Lundbäck, Andy West, Michael M. Hann, and Per Artursson.
Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery.
PNAS 2017 ; published ahead of print July 12, 2017, doi: 10.1073/pnas.1701848114.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]